Remove 2014 Remove COVID-19 Remove FDA Remove Licensing
article thumbnail

SQA Regulatory Surveillance Summary 4 | Monthly Update 2021

SQA

Due to the COVID-19 pandemic, there was an increase of 39.2% Commission in March 2015 after the publication, in December 2014, of the Q3D Guideline on Elemental Impurities (EI) by the International Council for Harmonization (ICH). on regulations published by ANVISA. The deadline for comments is 30 June 2021.

FDA 52
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – September/October

SQA

19 Medical Rehabilitation Equipment. 26 of 2014. Medicine shortages and reduced availability of medicine represent an increasing issue across the European Union (EU) and the globe, which has been amplified by the COVID-19 pandemic. United States Food and Drug Administration (FDA) – Regulations and guidance.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – June

SQA

ANVISA published the RDC 702/2022, which repeals some requirements that were instituted to speed market approval of devices needed to treat patients during the height of the COVID-19 pandemic. The Agency recently published the first list of critical medicines for the management of the COVID-19 pandemic.

FDA 91
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2024

SQA

The glossary was originally published in 2014 and has been used to define excipient terms and acronyms commonly found in IPEC guides. PCPC provided feedback to the FDA on the development of an efficient electronic submission program (Cosmetics Direct) and recognizes that the FDA’s development of Cosmetics Direct is ongoing.

FDA 52
article thumbnail

PREP Act Immunity: Baghikian v. Providence Health & Servs.

Drug & Device Law

Not to mention, it is a powerful defense for our clients in product liability matters because it can foreclose liability and plaintiffs’ use of tort lawsuits (invariably creatures of state law origin) to impose requirements on medical devices or pharmaceuticals that the federal FDA did not. What could be better than preemption? See 42 U.S.C.